Most current guidelines support the notion that screening should be considered for men starting at age 50 and should be offered earlier to men at high risk for prostate cancer (African Americans, men with positive family history of prostate cancer, and those who are BRCA1 or BRCA2 mutation carriers), beginning at age 40–45.45–48 These high-risk populations might benefit more from screening, although no high-level evidence is available. This evidence concerns the gene BRCA2 and prostate cancer.